LY518674

CAS No. 425671-29-0

LY518674( LY-674 )

Catalog No. M24391 CAS No. 425671-29-0

LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 240 In Stock
5MG 357 In Stock
10MG 530 In Stock
25MG 851 In Stock
50MG 1152 In Stock
100MG 1557 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LY518674
  • Note
    Research use only, not for human use.
  • Brief Description
    LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis.
  • Description
    LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα antagonist (EC50: 42 nM for human PPARα).
  • In Vitro
    ——
  • In Vivo
    LY518674 reduces triglycerides and increased HDL-C in vivo.LY518674 substantially increases apolipoprotein A-I (apoA-I) turnover without major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) .
  • Synonyms
    LY-674
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPARα
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    425671-29-0
  • Formula Weight
    409.48
  • Molecular Formula
    C23H27N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (610.53 mM; Need ultrasonic)
  • SMILES
    CC(C)(C(O)=O)Oc1ccc(CCCC(N2)=NN(Cc3ccc(C)cc3)C2=O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72.
molnova catalog
related products
  • Seladelpar

    A potent, selective, orally bioavailable PPARδ agonist for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

  • AZD 6610

    AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.

  • DG172 (dihydrochlori...

    DG172 (dihydrochloride) is an ?antagonist of ?PPARβ/δ(IC50 : 27 nM).